{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=32",
    "query": {
      "intervention": "Protein Control",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 3497,
    "total_pages": 350,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Protein+Control&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T01:39:32.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05877417",
      "title": "Blood Flow Restriction and Creatine Supplementation in Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Physical Inactivity"
      ],
      "interventions": [
        {
          "name": "Creatine Monohydrate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Blood Flow Restriction",
          "type": "DEVICE"
        },
        {
          "name": "Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 68,
      "start_date": "2023-05-17",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2024-06-12",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877417"
    },
    {
      "nct_id": "NCT02367040",
      "title": "Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lymphoma,Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "Copanlisib (Aliqopa, BAY80-6946)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 458,
      "start_date": "2015-08-03",
      "completion_date": "2024-11-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 16,
      "location_summary": "West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more",
      "locations": [
        {
          "city": "West Covina",
          "state": "California"
        },
        {
          "city": "Ashland",
          "state": "Kentucky"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02367040"
    },
    {
      "nct_id": "NCT04068610",
      "title": "COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Microsatellite-stable Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Oleclumab",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "101 Years",
        "sex": "ALL",
        "summary": "18 Years to 101 Years"
      },
      "enrollment_count": 61,
      "start_date": "2019-09-13",
      "completion_date": "2026-11-24",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Sacramento, California • Ann Arbor, Michigan + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04068610"
    },
    {
      "nct_id": "NCT00646425",
      "title": "The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-infectious Uveitis"
      ],
      "interventions": [
        {
          "name": "Basiliximab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerimon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 5,
      "start_date": "2008-05",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2010-08-19",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 6,
      "location_summary": "Cambridge, Massachusetts • Kansas City, Missouri • New York, New York + 3 more",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Belmont",
          "state": "North Carolina"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646425"
    },
    {
      "nct_id": "NCT02773368",
      "title": "A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes",
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "insulin degludec/liraglutide",
          "type": "DRUG"
        },
        {
          "name": "insulin glargine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2016-05-23",
      "completion_date": "2017-10-23",
      "has_results": true,
      "last_update_posted_date": "2020-08-11",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 24,
      "location_summary": "Glendale, Arizona • La Jolla, California • Mission Viejo, California + 21 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02773368"
    },
    {
      "nct_id": "NCT04377620",
      "title": "Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 211,
      "start_date": "2020-05-24",
      "completion_date": "2021-02-26",
      "has_results": true,
      "last_update_posted_date": "2022-01-19",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 35,
      "location_summary": "Scottsdale, Arizona • San Diego, California • Washington D.C., District of Columbia + 29 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377620"
    },
    {
      "nct_id": "NCT03679780",
      "title": "The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular Diseases",
        "Cardiovascular Risk Factor",
        "Vasoconstriction"
      ],
      "interventions": [
        {
          "name": "BQ-788",
          "type": "DRUG"
        },
        {
          "name": "BQ-123",
          "type": "DRUG"
        },
        {
          "name": "L-Arginine",
          "type": "DRUG"
        },
        {
          "name": "NG Nitro L Arginine Methyl Ester",
          "type": "DRUG"
        },
        {
          "name": "Sodium Nitroprusside",
          "type": "DRUG"
        },
        {
          "name": "Lactated Ringer's",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas at Arlington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 19,
      "start_date": "2018-10-01",
      "completion_date": "2023-07-26",
      "has_results": false,
      "last_update_posted_date": "2024-06-11",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 1,
      "location_summary": "Arlington, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03679780"
    },
    {
      "nct_id": "NCT00877890",
      "title": "A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "exenatide once weekly",
          "type": "DRUG"
        },
        {
          "name": "exenatide twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2009-03",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-04-07",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 38 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00877890"
    },
    {
      "nct_id": "NCT04160910",
      "title": "5HTP Regulation Of Asthma In Children",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild or Moderate Asthma With Allergic Sensitization"
      ],
      "interventions": [
        {
          "name": "5-Hydroxytryptophan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "8 Years to 18 Years"
      },
      "enrollment_count": 20,
      "start_date": "2021-02-11",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04160910"
    },
    {
      "nct_id": "NCT00131508",
      "title": "Trial of Oral Glutamine in Patients With Sickle Cell Anemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "Glutamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "5 Years to 18 Years"
      },
      "enrollment_count": 27,
      "start_date": "2004-05",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-10-26T01:39:32.956Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00131508"
    }
  ]
}